Fasiglifam (TAK-875)
TAK-875_310
Phase 3 small_molecule terminated
Quick answer
Fasiglifam (TAK-875) for Diabetes Mellitus, Type 2 is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Diabetes Mellitus, Type 2
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated